CLL
Supportive Care and Other Tools for Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In patients who received prior CLL/SLL-directed therapy but require additional treatment, decisions may depend on ...
APRIL 29, 2025
Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CLL is a lymphoproliferative disorder characterized by the accumulation of circulating mature B cells that are ...
MARCH 20, 2024
Key Treatment Principles and Recent Updates In the Management of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CLL and SLL are different manifestations of the same underlying disease process.
MAY 24, 2023
New CLL Data Point to ‘Durable, Lasting Response’
Aseries of studies and trials conducted in chronic lymphocytic leukemia suggest that an increasing proportion of ...
SEPTEMBER 17, 2021
Study Identifies Cardiovascular Toxicities Associated With Ibrutinib
The study identified several cardiovascular toxicities associated with ibrutinib, including supraventricular ...
SEPTEMBER 26, 2019
First-Line Ibrutinib-Based Rx More Effective, Less Toxic Than Standard for Younger CLL Patients
First-line treatment combining ibrutinib and rituximab (significantly improves progression-free survival and ...
JANUARY 17, 2019
FDA Approves Copiktra for Relapsed or Refractory CLL, SLL
Duvelisib is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of ...
SEPTEMBER 25, 2018
Venclexta Approved for CLL/SLL After 1 Prior Therapy
The FDA granted regular approval to venetoclax in patients with chronic lymphocytic leukemia (CLL) or small ...
JUNE 18, 2018
Rituxan Hycela Approved for FL, DLBCL, CLL
Rituximab and hyaluronidase human (Rituxan Hycela, Genentech) was approved for subcutaneous injection for the ...
JUNE 23, 2017
FDA Approves Venclexta for Certain CLL in Patients
Venclexta is the first BCL-2 inhibitor in relapsed/refractory CLL patients with 17p deletion.
APRIL 12, 2016
